CTKB Stock Cash Flow Statements

Cytek BioSciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Cytek BioSciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30

cash flows from operating activities:
net income	-5,583,000	-11,402,000	9,643,000	940,000	-10,434,000	-6,169,000	5,503,000	-6,456,000	-4,388,000	-6,807,000	3,718,000	1,626,000	-702,000	-2,158,000	-1,165,000	1,420,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	1,890,000	1,875,000	1,854,000	1,851,000	1,808,000	1,699,000	1,631,000	1,767,000	1,649,000	1,001,000	761,000	72,000	865,000	794,000	685,000	189,000
amortization of operating lease-right-of use assets	1,098,000	1,009,000			672,000	761,000	794,000	792,000	796,000	800,000	1,103,000	699,000	689,000	676,000
stock-based compensation	6,790,000	6,630,000	7,003,000	7,053,000	7,152,000	5,640,000	5,669,000	5,758,000	5,922,000	4,699,000	4,465,000	4,359,000	3,934,000	3,837,000	3,008,000	2,455,000
loss on disposal of property and equipment	152,000	101,000	3,000	0	5,000	47,000	0
benefit from credit losses						121,000
benefit from excess and obsolete inventory	21,000	314,000	268,000	341,000	125,000	912,000	670,000	202,000	88,000	508,000	294,000	175,000	213,000	74,000	155,000	70,000
deferred income taxes	-2,056,000	-336,000
loss on investments, accretion, and amortization	-1,615,000	-1,493,000
interest expenses for accretion of the legal settlement liabilities	144,000	148,000	-7,704,000	65,000	146,000	301,000	266,000	480,000	287,000	544,000	567,000	564,000	549,000	498,000	475,000	439,000
change in operating assets and liabilities:
trade accounts receivable	652,000	6,449,000	-9,329,000	-6,252,000	5,918,000	4,235,000	263,000	-6,850,000	-6,800,000	6,055,000	-7,964,000	-3,816,000	-6,926,000	-1,038,000	-720,000	-5,593,000
inventories	-3,570,000	-1,503,000	2,000,000	3,556,000	4,426,000	4,773,000	6,333,000	-1,888,000	3,029,000	-3,188,000	1,884,000	-5,182,000	-8,434,000	-5,921,000	-2,230,000	-964,000
prepaid expenses and other assets	-270,000	-149,000	-742,000	-2,610,000	3,468,000	-2,925,000	-7,179,000	833,000	-3,033,000	-136,000	-4,327,000	-6,371,000	-4,313,000	-4,351,000	-1,250,000	-2,445,000
trade accounts payable	759,000	410,000	258,000	2,228,000	-519,000	615,000	-1,794,000	1,709,000	-2,004,000	305,000	-908,000	-907,000	895,000	2,782,000	-742,000	635,000
accrued expenses and other liabilities	2,791,000	-2,121,000	2,938,000	5,634,000	-4,790,000	-4,599,000	119,000	335,000	-1,488,000	1,763,000	4,642,000	44,000	2,229,000	555,000	8,879,000	1,594,000
legal settlement liabilities	-223,000	-365,000	-1,116,000	81,000	-3,000	-67,000	76,000	-164,000	141,000	-351,000	-105,000	-55,000	51,000	482,000	-5,305,000	647,000
operating lease liabilities	-1,162,000	-1,035,000		-1,140,000	-433,000	-727,000
deferred revenue	238,000	1,343,000	1,393,000	1,762,000	40,000	542,000	-696,000	1,495,000	5,770,000	-49,000	2,915,000	1,898,000	2,017,000	2,581,000	3,375,000	2,714,000
net cash from operating activities	108,000	-125,000	1,997,000	13,221,000	6,204,000	3,957,000	9,512,000	-4,239,000	-2,850,000	2,858,000	6,193,000	-7,504,000	-9,440,000	-1,480,000	5,448,000	1,161,000
capex	-1,577,000	-849,000	-894,000	-1,011,000	-1,053,000	-567,000	-1,500,000	-1,330,000	-1,313,000	-505,000	-6,530,000	-1,110,000	-1,328,000	-780,000	-1,296,000	-1,308,000
free cash flows	-1,469,000	-974,000	1,103,000	12,210,000	5,151,000	3,390,000	8,012,000	-5,569,000	-4,163,000	2,353,000	-337,000	-8,614,000	-10,768,000	-2,260,000	4,152,000	-147,000
cash flows from investing activities:
purchases of marketable securities	-81,262,000	-60,161,000	-107,250,000	-52,827,000	-36,853,000	-77,132,000	-23,372,000	-23,482,000	-5,842,000	-123,239,000
proceeds from maturities of marketable securities	66,475,000	70,431,000		38,000,000	40,000,000	72,000,000		68,000,000
proceeds from sale of property and equipment	23,000	33,000		21,000
purchase of property and equipment	-1,577,000	-849,000	-894,000	-1,011,000	-1,053,000	-567,000	-1,500,000	-1,330,000	-1,313,000	-505,000	-6,530,000	-1,110,000	-1,328,000	-780,000	-1,296,000	-1,308,000
purchase of intangible assets	-74,000	-2,000	-9,000	8,000	-148,000	-55,000	-61,000	-63,000			-80,000
net cash from investing activities	-16,413,000	9,452,000	-63,433,000	-15,809,000	2,022,000	-5,754,000	29,066,000	43,124,000	2,790,000	-168,874,000	-51,064,000	-1,150,000	-2,915,000	-780,000	-18,296,000	-1,308,000
cash flows from financing activities:
repayment of loan	-142,000	-1,518,000	-139,000	-140,000	-139,000	-139,000	-140,000	-138,000	-141,000	-146,000
proceeds from employee stock purchase plan			697,000	0			889,000	0			820,000	0
payments for taxes related to net share settlement of equity awards	-102,000	-129,000	-130,000	-146,000	-130,000	-148,000	-102,000	-149,000	-111,000	-57,000	-71,000	-71,000
proceeds from issuance of common stock under employee stock plans	64,000	39,000	138,000	147,000	224,000	506,000	341,000	441,000	483,000	203,000	168,000	226,000
proceeds from line of credit	1,385,000	690,000	2,785,000	5,000	-3,000	1,394,000
payments for repurchase of shares	-4,510,000	-10,627,000		-11,950,000				-8,428,000
net cash from financing activities	-2,602,000	-11,545,000	-3,640,000	-12,084,000	-1,711,000	1,613,000	-33,754,000	-8,274,000			3,850,000	155,000	1,144,000	364,000	17,000	217,078,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	-921,000	-1,228,000	1,518,000	-943,000	2,262,000	1,695,000	-823,000	1,474,000	-1,006,000	-1,090,000					678,000	-6,000
cash, cash equivalents and restricted cash:
net increase in cash, cash equivalents and restricted cash	-19,829,000	-3,446,000			8,777,000	1,511,000									-12,153,000	216,925,000
cash, cash equivalents and restricted cash at beginning of period	0	98,745,000	0	0	0	167,630,000	0	0	0	299,500,000					0	0
cash, cash equivalents and restricted cash at end of period	-19,829,000	95,299,000	-63,558,000	-15,615,000	8,777,000	169,141,000	4,001,000	32,085,000	-850,000	132,394,000					-12,153,000	216,925,000
supplemental disclosure of cash flow information:
cash paid for taxes			1,906,000	864,000			4,495,000	127,000	590,000	93,000	460,000	2,273,000	7,582,000	75,000	625,000	231,000
non-cash investing and financing activities:
fixed asset purchases in accounts payable or accrued purchase at period end	-194,000	234,000		-24,000	-165,000	288,000
transfer of inventory to property and equipment
intangible asset in accounts payable or accrued expenses at period end	-31,000	47,000				46,000
operating lease right-of-use assets obtained in exchange for operating lease liabilities	7,434,000	599,000
allowance for credit losses
gain on investments, accretion, and amortization			-1,580,000	-1,246,000	-1,183,000	-1,202,000	-1,396,000	-1,561,000	-2,124,000	-1,580,000
lease liabilities									-709,000	-706,000	-877,000	-610,000	-507,000	-291,000
maturities of marketable securities
proceeds from sales of property and equipment
acquisition of business							0	-1,000	0	-44,895,000
payment for investment											0
payment for additional investment in cytek japan, net of cash acquired															0	0
payment for repurchase of shares
proceeds from loan
net decrease in cash, cash equivalents and restricted cash			-63,558,000					32,085,000	-850,000	-167,106,000
fixed asset purchases in accounts payable at period end								66,000	-109,000	139,000	-168,000	-16,000	23,000	228,000	-175,000	-29,000
amortization of operating lease right-of-use assets
(benefits from) benefit from credit losses				0
payment for additional investment in cytek japan								0	0	-235,000
derecognition of right-of-use assets
gain on equity method investment															0	0
loss on lease exit cost
repayment of paycheck protection program loan															0	0
proceeds from initial public offering, net of underwriting discounts and commissions and other offering costs															0
increase in accounts receivable allowance for credit losses								41,000
payment of investment
intangible asset in accrued expenses at period end								1,000	4,000	4,000	-39,000	29,000	0	40,000	3,000
allowance for doubtful accounts
proceeds from paycheck protection program loan
net proceeds from issuance of series d redeemable convertible preferred stock
stock option exercise in other receivables at period end
common stock issuance for legal settlement
effect of exchange rate changes on cash and cash equivalents												128,000	-1,401,000	-216,000
cash and cash equivalents:
net increase in cash and cash equivalents												-8,371,000	-12,612,000	-2,112,000
cash and cash equivalents at beginning of period												0	0	364,618,000
cash and cash equivalents at end of period												-8,371,000	-12,612,000	362,506,000
payment of deferred offering cost
stock option exercise in accounts receivable at period end
deferred financing costs in accounts payable at period end
proceeds from issuance of common stock upon exercise of stock options														364,000	17,000	308,000
payment of deferred offering costs
deferred offering costs in accrued expenses at period end

We provide you with 20 years of cash flow statements for Cytek BioSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cytek BioSciences stock. Explore the full financial landscape of Cytek BioSciences stock with our expertly curated income statements.

The information provided in this report about Cytek BioSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.